Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Jaroszewicz, Jerzy ^a,f,g   Reiberger, Thomas ^b   Meyer Olson, Dirk ^a,g   Mauss, Stefan ^c   Vogel, Martin ^d,g   Ingiliz, Patrick ^e   Payer, Berit Anna ^b   Stoll, Matthias ^a,g   Manns, Michael P ^a,g   Schmidt, Reinhold E ^a,g   Flisiak, Robert ^f   Wedemeyer, Heiner ^a,g   Peck Radosavljevic, Markus ^b   Rockstroh, Jürgen ^d,g   Cornberg, Markus ^a,g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Center for HIV and Hepatogastroenterology   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e Medical Center for Infectious Diseases (MIB)   (Germany)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g German Center for Infectious Disease Research (DZIF)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; COMBINATION ANTIRETROVIRAL THERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE STATUS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; ANTI-RETROVIRAL AGENTS; AUSTRIA; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GERMANY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLAND; RETROSPECTIVE STUDIES;

EID: 84865048824     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043143     Document Type: Article

References (22)

1. European Association for the Study of the Liver, ((2012)) EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 57:: 167--185.
2. Cornberg M, Jaroszewicz J, Manns MP, Wedemeyer H, ((2010)) Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol. 56:: 451--465.
3. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, et al. ((2011)) Hepatitis B surface antigen Quantification: Why and How to use it in 2011- A Core Group Report. J Hepatol 55:: 1121--31.
4. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, et al. ((2009)) Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 49:: 1141--1150.
5. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, et al. ((2010)) Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 54:: 449--54.
6. Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, et al. ((2011)) Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 16:: 915--924.
7. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, et al. ((2010)) Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 52:: 514--522.
8. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, et al. ((2010)) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52:: 508--513.
9. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, et al. ((2010)) Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139:: 483--490.
10. Alter MJ, ((2006)) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44:: S6--9.
11. Thio CL, ((2003)) Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 23:: 125--136.
12. van Bommel F, Wunsche T, Schurmann D, Berg T, ((2002)) Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36(2):: 507--508.
13. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, et al. ((2011)) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 140:: 132--143.
14. Tuma P, Medrano J, Resino S, Vispo E, Madejon A, et al. ((2010)) Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 15:: 881--886.
15. Martin-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, et al. ((2011)) Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 25:: 73--79.
16. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, et al. ((2011)) Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir Ther 16:: 199--205.
17. Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, et al. ((2012)) Kinetics of HBs and HBe antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-HBV infected patients. AIDS 26:: 939--949.
18. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL, ((2011)) Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 204:: 415--418.
19. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, et al. ((2010)) Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51:: 1933--1944.
20. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, et al. ((2010)) Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52:: 1611--1620.
21. Rehermann B, ((2007)) Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 27:: 152--160.
22. Chen CJ, Lee MH, Liu J, Batrla-Utermann R, Jen CL, et al. ((2011)) Quantitative serum levels of hepatitis B virus DNA and surface antigen are independent risk predictors of hepatocellular carcinoma. Hepatology 54:: 881A--881A.